Skip Navigation Links

Gerard Zurawski, PhD






Director, Center for Biotechnology


Contact Information

3410 Worth St., Suite 600

Dallas, TX 75246





University of Sydney, Australia

BSc Hons Class I - Microbiology

PhD - Department of Genetics, School of Biology


Stanford University, California

Postdoctoral Fellow, School of Biological Sciences


Commonwealth Scientific and Industrial Research Organization, Canberra

Queen Elizabeth II Fellow in the Division of Plant Industry



Major Contributions to Science


  • Studies of the control of bacterial operons via translational regulation of transcription. [G. Zurawski, D. Elseviers, G.V. Stauffer and C. Yanofsky.  Translational control of transcription termination at the attenuator of the Escherichia coli trp operon (1978). Proc. Natl. Acad. Sci. USA, 75:  5988‑5992.]
  • Structure, function, and evolution of chloroplast DNA. [E.M. Golenberg, D.E. Giannasi, M.T. Clegg, C.J. Smiley, M. Durbin, D. Henderson and   G. Zurawski.  Chloroplast DNA from a Miocene Magnolia species (1990).  Nature, 344, 656‑658.]
  • Nature of interactions between cytokines and their receptor complexes. [S.M. Zurawski and G. Zurawski.  Receptor antagonist and selective agonist derivatives of mouse interleukin‑2 (1992). EMBO J., 11, 3905‑3910.]
  • Discovery, biology, and receptor complexes of interleukin-13. [A.N.J. McKenzie, J.A. Culpepper, R. de Waal Malefyt, F. Briere, J. Punnonen, G. Aversa, A. Sato, W. Dang, B.G. Cocks, S. Menon, J.E. de Vries, J. Banchereau, and G. Zurawski. Interleukin‑13, a novel T cell‑derived cytokine that regulates human monocyte and B cell function (1993). Proc. Natl. Acad. Sci. USA, 90, 3735‑3739.]
  • Directed a genomics program at the DNAX Research Institute that discovered numerous cytokines and their receptors, including IL-19, IL-22, IL-23, IL-25, IL-27, IL-33, and TSLP. [M.M. Fort,  J. Cheung, D. Yen, Y.-J. Liu, S.M.  Zurawski, S. Lo, S. Menon, T. Clifford, B. Hunte, R. Lesley, T. Muchamuel, S.D. Hurst, G. Zurawski, M.W. Leach, D.M. Gorman, and D.M. Rennick. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo (2001). Immunity, 15, 985-995.]
  • Directing a program of vaccine development at BIIR based on targeting antigens directly to dendritic cells. [Dapeng LI 2012 J. Ex. Med paper]



Key Patents


1. Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody. Patent# US7786267


2. Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells. Patent# US8057798, US8449888, US9102730, US8586052


3. Agents That Engage Antigen-Presenting Cells through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR). Patent# US8236934, US8728481


4. HIV Vaccine Based on Targeting Maximized Gag and Nef to Dendritic Cells. Patent# US9109011


5. Antigen Presenting Cell Targeted Anti-Viral Vaccines. Patent# US8518410


6. Fusion Proteins Comprising Antibody and HPV E6 and E7 Antigens. Patent# US9102734


7. Activation of Human Antigen-Presenting Cells through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1). Patent# US8481314


8. Anti-CD40 Targeted Fusion Proteins. Patent# US8961991



Current Grants  


Antibody-Based Combination Therapy against Prostate Cancer

American Cancer Society Research Scholar, American Cancer Society 

SangKon Oh (PI); Role: Co-Investigator


Preclinical study for testing prostate cancer vaccines carried by anti-CD40 mAb in combination of anti-OX40L mAb to potentiate immunity against tumor.


DC-ASGPR as a Novel Target for Controlling GVHD and Allograft Rejection (1R01AI105066)

SangKon Oh (PI); Role: Co-Investigator

National Institute of Allergy and Infectious Diseases


The major goal is to determine if targeting DC-ASGPR prevents GVHD and allograft rejection without interfering with host immunity to infections.


EU Horizon 2020 Consortium

European Commission

Yves Levy (PI); Role: Co-Investigator


Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS

Consortium to develop and test HIV/AIDS vaccines - combining best-in-class protein and viral/DNA vectors.


DC-Targeting HIV Vaccines

VRI, ANRS Vaccine Research Institute

Gerard Zurawski (PI)


The major goals of this project are to develop HIV vaccines.



Publications (total of 94 from 1975-2015)

Key publications during the past 5 years (2010-2015)

Click here for complete bibliography.


Flamar AL, Contreras V, Zurawski S, Montes M, Dereuddre-Bosquet N, Martinon F, Banchereau J, Le Grand R, Zurawski G, Levy Y. Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo. PLoS One. 2015 Sep 25;10(9):e0135513. doi: 10.1371/journal.pone.0135513. eCollection 2015. PubMed PMID: 26407317; PubMed Central PMCID: PMC4583231.


Joo H, Li D, Dullaers M, Kim TW, Duluc D, Upchurch K, Xue Y, Zurawski S, Le Grand R, Liu YJ, Kuroda M, Zurawski G, Oh S. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity. 2014 Oct 16;41(4):592-604. doi: 10.1016/j.immuni.2014.09.009. Epub 2014 Oct 9. PubMed PMID: 25308333; PubMed Central PMCID: PMC4221489.


Skinner JA, Zurawski SM, Sugimoto C, Vinet-Oliphant H, Vinod P, Xue Y, Russell-Lodrigue K, Albrecht RA, García-Sastre A, Salazar AM, Roy CJ, Kuroda MJ, Oh S, Zurawski G. Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment. Clin Vaccine Immunol. 2014 Dec;21(12):1668-80. doi: 10.1128/CVI.00547-14. Epub 2014 Oct 8. PubMed PMID: 25298110; PubMed Central PMCID: PMC4248778.


Flamar AL, Xue Y, Zurawski SM, Montes M, King B, Sloan L, Oh S, Banchereau J, Levy Y, Zurawski G. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS. 2013 Aug 24;27(13):2041-51.


Flamar AL, Zurawski S, Scholz F, Gayet I, Ni L, Li XH, Klechevsky E, Quinn J, Oh S, Kaplan DH, Banchereau J, Zurawski G. Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J Immunol. 2012 Sep 1;189(5):2645-55.


Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, O'Garra A, Zurawski G, Banchereau J, Oh S. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012;16:109-21.


Klechevsky E, Flamar A-L, Cao Y, Blanck J-P, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010;116:1685-97.  


Ni L, Gayet I, Zurawski S, Duluc D, Flamar A-L, Li X-H, O’Bar A, Clayton S, Palucka AK, Zurawski G, Banchereau J, Oh SK. Concomitant activation and antigen uptake via human Dectin-1 results in potent antigen-specific CD8+ T Cell responses. J Immunol2010;185:3504-13.


Ni L, Li X-H, Ingrid G, Duluc D, Klucar P, Clayton S, Zurawski S, Palucka AK, Zurawski G, Banchereau J, Oh SK. The role of human Dectin-1 in eliciting antigen specific CD8+ T cell responses. J Immunol 2010;184 :130-5.  



Copyright © 2015 Baylor Scott & White Health All Rights Reserved.   |   3500 Gaston Avenue, Dallas, TX 75246-2017   |   1.800.9BAYLOR
Site Map   |   Privacy Terms & Patient Rights   |   Terms of Use